CompletedPhase 4ACTRN12612000002886

Does a continuous low-dose antibiotic treatment lower the rates of urinary tract infections and stent related symptoms in patients with ureteral stents compared to a periinterventionel prophylaxis only?

For patients with ureteral stents does the use of a continuous low-dose antibiotic treatment reduce the risk of urinary tract infections and stent related symptoms compared with periinterventional antibiotic prophylaxis only?


Sponsor

Department of Urology, University Hospital Bern

Enrollment

88 participants

Start Date

Mar 1, 2005

Study Type

Interventional

Conditions

Summary

The implantation of double J stents is a widely used intervention in the management of patients suffering from obstructing urinary stones. Nevertheless, two main complications are frequent, namely urinary tract infection (UTI) and stent related symptoms (SRS). The reported rates for UTI range from 2% to 34%. Risk factors known to particularly increase the incidence of clinically relevant UTIs are various i.e. underlying systemic disease (e.g. diabetes mellitus, chronic renal failure), female gender or stent indwelling time. SRS such as dysuria, flank pain, hematuria and/or increased voiding frequency are common and can seriously impact daily activities, impair sexual function and even decrease work capacity. Therefore UTI and SRS can significantly reduce patient’s quality of life and consecutively lead to an increase of healthcare costs. For the prevention of UTI a periinterventional antibiotic prophylaxis during double J stent implantation is recommended by the European Association of Urology. However, there is a lack of evidence for the exact antibiotic strategy regarding the entire double J stent indwelling time. In the clinical routine it is a common and widely used practice among urologists to continue a low dose antibiotic treatment for the entire stent indwelling time with the conception to reduce the prevalence of UTI and to possibly obtain a positive effect on SRS rates. To the best of our knowledge there exists neither evidence for the benefit nor for possible disadvantages of such an established empiric prevention. We therefore compared UTI and SRS rates in patients given a continuous low-dose antibiotic treatment for the entire stent indwelling time versus periinterventional antibiotic prophylaxis only. Additionally, the impact of drug side effects, potentially limiting the use of long-term antibiotics, was analyzed.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 90 Yearss

Plain Language Summary

Simplified for easier understanding

This study examines whether taking a continuous low-dose antibiotic while a ureteral stent is in place reduces urinary tract infections and stent-related symptoms compared to a single dose at the time of insertion, in adults aged 18-90 with urinary stones. Participants must have a sterile urine culture and not have taken antibiotics in the past two weeks. Those with staghorn kidney stones, fever, or urinary catheters are excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

We compared the rates of UTI and SRS in patients with urinary stones and an indication for a temporary double J stent placement given a perioperative prophylaxis only (arm 1) versus rates in patients

We compared the rates of UTI and SRS in patients with urinary stones and an indication for a temporary double J stent placement given a perioperative prophylaxis only (arm 1) versus rates in patients with a continous low dose antibiotic treatment until stent withdrawal (arm 2). All patients received a periinterventional antibiotic prophylaxis with 1,2g amoxicillin/clavulanic acid that was given intravenously at anaesthesia induction in order to obtain a peak concentration at the time of highest risk during the procedure. According to the local pathogen’s profile and susceptibility to different antibiotics, the antimicrobial agent of choice for continuous low dose treatment was amoxicillin/clavulanic acid (625mg once daily). Patients with allergies against penicillin received either trimethoprim/sulfamethoxazole (80mg/400mg once daily) or ciprofloxacin (250mg once daily).


Locations(1)

Bern, Switzerland

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000002886